The incidence rate of chronic graft versus host disease (cGVHD) after bone marrow transplantation is as high as 30%~70%. Professor You Jianhua, Executive Director of the Hematology Department of Hainan Hospital Affiliated to Ruijin Hospital of Shanghai Jiao Tong University, emphasized in an interview with reporters on the 19th that "it is crucial to detect chronic graft-versus-host disease as early as possible, especially to pay attention to" preemptive intervention "for tissue fibrosis in the early stages of the disease." Professor You Jianhua introduced that chronic graft-versus-host disease is caused by transplanted immune cells (grafts) attacking the patient's (host's) cells, damaging the original immune system of the self, leading to inflammation and fibrosis in multiple tissues. (cGVHD) often goes through three stages, with over half of patients diagnosed at the hospital at a moderate to severe level. He explained that this is because the three stages are usually continuous and can occur simultaneously, meaning that patients in the first stage may enter both the second and third stages simultaneously. As the Executive Director of the Hematology Department of Hainan Hospital, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Professor You Jianhua shared clinical cases. In 2019, 7-year-old Shuo Shuo (pseudonym) received a bone marrow transplant. Originally, the family thought that after a bone marrow transplant, Shuo Shuo would completely bid farewell to the repeated torment of illness. However, in 2020, Shuo Shuo developed severe chronic graft-versus-host disease with fibrosis, with rejection and fibrosis extending to his skin, joints, mouth, and eyes. He even entered the pediatric ICU due to severe pneumonia and respiratory failure. Guo Yu, 38 years old this year (pseudonym), also developed symptoms of chronic graft-versus-host disease with fibrosis, including cystitis, lung rejection, oral rejection, and eye rejection, after bone marrow transplantation. Professor You Jianhua introduced, "Currently, the treatment of chronic graft-versus-host disease is mainly based on immunosuppressive therapy. Long term use can inhibit the body's own immune system, increase the risk of recurrence of primary diseases, especially difficult to solve fibrosis problems, making fibrosis problems continue to worsen. Traditional anti rejection drugs mainly target the skin, but the clinical effectiveness rate for fibrosis, especially pulmonary fibrosis, is even less than 10%. Patients urgently need innovative treatment plans." Master's mother told reporters, "In recent years, we have visited several hospitals, crossed several provinces and cities, used four or five anti rejection drugs, but still cannot control serious rejection reactions." It is understood that currently, innovative drugs are needed. "The treatment plan targets ROCK2, a novel target for the treatment of chronic graft-versus-host disease. Professor You Jianhua told reporters that in August 2023, immune modulators targeting the ROCK2 target will be approved in China for the treatment of cGVHD patients aged 12 and above who have insufficient response to glucocorticoids or other systemic therapies. On the one hand, they can restore the patient's immune homeostasis, and on the other hand, they can effectively achieve anti fibrotic effects, prevent the formation of fibrosis from the source, and directly act on fibrotic components, reduce fibrosis, and restore patient confidence in life. You Jianhua said that Shuo Shuo has been receiving treatment for over 5 months. Currently, apart from partial relief of fibrosis in the skin, eyes, and joints, the child's oral, esophageal, and gastrointestinal tracts have achieved complete relief. Guo Yu stated that after 5 weeks of treatment, his qi